Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and Erlotinib in Metastatic Colorectal Cancer
NCT02723578Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Dec 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and erlotinib in metastatic colorectal cancer (mCRC), sponsored by Yonsei University. Primary endpoints: Overall Response Rate up to 2 years and Progression-Free Survival up to 2 years. Started Dec 2015; status: completed.
02
Drugs
pemetrexederlotinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02723578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723578.